https://doi.org/10.4081/aiua.2025.13412
Discovering a new nutraceutical based on pollen extract and teupolioside: a prospective monocentric study evaluating its role in alleviating lower urinary tract symptoms in benign prostatic hyperplasia patients
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 28 March 2025
Background: Benign prostatic hyperplasia (BPH) is a common condition in men over 50, leading to lower urinary tract symptoms (LUTS). A nutraceutical containing pollen extract (Graminex® G96®) and teupolioside has shown potential in alleviating LUTS by targeting inflammation and dihydrotestosterone production. This prospective, monocentric study enrolled 60 patients with mild to moderate LUTS due to BPH.
Methods: Participants received one tablet daily for three months. Assessments included the international prostate symptom score (IPSS), quality of life (QoL), uroflowmetry, postvoid residual (PVR), and sexual function (IIEF-5, MSHQ EjD).
Results: Fifty-three patients completed the follow-up. Significant improvements were observed in IPSS and QoL (p<0.001), with scores decreasing from 14 (11-16) at baseline to 10 (8-12) at three months and decreasing from 3 (2-3) to 2 (2-2), respectively. Uroflowmetry parameters (Qmax and PVR) improved, increasing from 12 (11-16) ml/s to 15 (11-17) ml/s and decreasing from 50 (30-55) ml to 35 (25-45) ml, respectively, without statistical significance (p>0.05). Sexual function and PSA levels remained stable, with no significant adverse effects reported.
Conclusions: The combination of pollen extract and teupolioside effectively alleviates LUTS in BPH patients with a favorable safety profile, particularly in avoiding sexual dysfunction.
Downloads
Kevin T. McVary MF. BPH: Epidemiology and Comorbidities. 2006; 12. Accessed August 26, 2024. https://www.ajmc.com/view/
apr06-2288ps122-s128.
Nickel JC, Roehrborn CG, O’Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms:
examination of baseline data from the REDUCE trial. Eur Urol. 2008; 54:1379-1384. DOI: https://doi.org/10.1016/j.eururo.2007.11.026
Zhou Z, Cui Y, Wu J, et al. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol. 2019; 19:17. DOI: https://doi.org/10.1186/s12894-019-0446-8
Liguori G, Trombetta C, De Giorgi G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med. 2009; 6:544-552. DOI: https://doi.org/10.1111/j.1743-6109.2008.01109.x
Korkina LG, Mikhal’chik EV, Suprun MV, et al. Molecular mechanisms underlying wound healing and anti-inflammatory properties of naturally occurring biotechnologically produced phenylpropanoid glycosides. Cellular and Molecular Biology TM. 2007; 53:84-91.
Locatelli M, Macchione N, Ferrante C, et al. Graminex Pollen: Phenolic Pattern, Colorimetric Analysis and Protective Effects in
Immortalized Prostate Cells (PC3) and Rat Prostate Challenged with LPS. Molecules. 2018; 23:1145. DOI: https://doi.org/10.3390/molecules23051145
Cai T, Gallelli L, Cione E, et al. The efficacy and tolerability of pollen extract in combination with hyaluronic acid and vitamins in the management of patients affected by chronic prostatitis/chronic pelvic pain syndrome: a 26 weeks, randomized, controlled, singleblinded, phase III study. Minerva Urol Nephrol. 2022; 74:780-788. DOI: https://doi.org/10.23736/S2724-6051.21.04141-2
Habib FK, Ross M, Lewenstein A, et al. Identification of a prostate inhibitory substance in a pollen extract. Prostate. 1995; 26:133-39. DOI: https://doi.org/10.1002/pros.2990260305
Matsukawa Y, Naito Y, Funahashi Y, et al. Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study. Neurourol Urodyn. 2020; 39:1994-2002. DOI: https://doi.org/10.1002/nau.24454
Cai T, Verze P, La Rocca R, et al. The role of flower pollen extract in managing patients affected by chronic prostatitis/chronic pelvic pain syndrome: a comprehensive analysis of all published clinical trials. BMC Urol. 2017; 17:32. DOI: https://doi.org/10.1186/s12894-017-0223-5
Muraca L, Scuteri A, Burdino E, et al. Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus
Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study. Life (Basel). 2022; 12:965. DOI: https://doi.org/10.3390/life12070965
Franco JVA, Trivisonno L, Sgarbossa NJ, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database Syst Rev. 2023; 6:CD001423. DOI: https://doi.org/10.1002/14651858.CD001423.pub4
Novara G, Giannarini G, Alcaraz A, et al. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus. 2016; 2:553-561. DOI: https://doi.org/10.1016/j.euf.2016.04.002
Cindolo L, Pirozzi L, Fanizza C, et al. Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study. Eur Urol. 2015; 68:418-425. DOI: https://doi.org/10.1016/j.eururo.2014.11.006
Bapir R, Bhatti KH, Eliwa A, et al. Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis. Arch Ital Urol Androl. 2022; 94:252-263. DOI: https://doi.org/10.4081/aiua.2022.2.252
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.